Image source: Getty Images.
Who said mergers and acquisitions (M&A) were slowing down in the drug industry? Certainly not healthcare conglomerate Johnson & Johnson (NYSE: JNJ), which has made two bids now to acquire Swiss drugmaker Actelion (NASDAQOTH: ALIOF).